Drugs Made In America Acquisition II - DMII Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.97
▼ -0.01 (-0.10%)

This chart shows the closing price for DMII by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Drugs Made In America Acquisition II Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMII and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMII

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Drugs Made In America Acquisition II in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.97.

This chart shows the closing price for DMII for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Drugs Made In America Acquisition II.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/3/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/2/2026Weiss RatingsInitiated CoverageSell (E)
(Data available from 3/3/2021 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/3/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/3/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/2/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/1/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/3/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Drugs Made In America Acquisition II logo
Drugs Made In America Acquisition II Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success. Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions. In the end, we will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders. Our executive offices are located in Fort Lauderdale, FL.
Read More

Today's Range

Now: $9.97
Low: $9.97
High: $9.98

50 Day Range

MA: N/A

52 Week Range

Now: $9.97
Low: $9.86
High: $10.01

Volume

356,682 shs

Average Volume

144,913 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Drugs Made In America Acquisition II?

The following equities research analysts have issued stock ratings on Drugs Made In America Acquisition II in the last twelve months: Weiss Ratings.
View the latest analyst ratings for DMII.

What is the current price target for Drugs Made In America Acquisition II?

0 Wall Street analysts have set twelve-month price targets for Drugs Made In America Acquisition II in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Drugs Made In America Acquisition II in the next year.
View the latest price targets for DMII.

What is the current consensus analyst rating for Drugs Made In America Acquisition II?

Drugs Made In America Acquisition II currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe DMII will underperform the market and that investors should sell shares of Drugs Made In America Acquisition II.
View the latest ratings for DMII.

What other companies compete with Drugs Made In America Acquisition II?

How do I contact Drugs Made In America Acquisition II's investor relations team?

Drugs Made In America Acquisition II's physical mailing address is 1 EAST BROWARD BOULEVARD, SUITE 700, FORT LAUDERDALE, FL, 33301. The company's listed phone number is (954) 870-3104. Learn More about contacing Drugs Made In America Acquisition II investor relations.